PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan
Status: RECRUITING
Study type: OBSERVATIONAL
Conditions: Breast Neoplasms|Breast Cancer|Neoplasm Metastasis
Sponsor: AstraZeneca
Collaborators: Daiichi Sankyo